17. Trade and other receivables and other current assets

Notes to the consolidated financial statements
CSR report

 

31 December

(thousands of €)

2020

2019

Non-current trade receivables

50,000

-

Trade receivables

134,632

39,603

Prepayments

219

292

Other receivables

13,568

14,114

Trade and other receivables

148,418

54,009

Inventories

355

255

Accrued income

1,096

4,443

Deferred charges

10,502

4,439

Other current assets

11,953

9,138

Total trade and other receivables & other current assets

210,371

63,147

Non-current and current trade and other receivables increased primarily due to the outstanding receivable as at 31 December 2020 of €160.0 million on Gilead related to the recently renegotiated agreement of December 2020 for filgotinib. We refer to note 2 Summary of significant transaction for more details.

We consider that the carrying amount of trade and other receivables approximates their fair value.

The other current assets mainly included accrued income from subsidy projects and deferred charges.

On 31 December 2020, we did not have any provision for expected credit losses.